Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.35 |
| ▸ | MEF2D | Q14814 | 4/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 5/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12037811 | 0.92 | SIRT2 (0.40) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL277489 | 0.90 | SIRT2 (0.41) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL14753623 | 0.88 | SIRT2 (0.38) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL16441084 | 0.86 | SIRT2 (0.36) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL12692606 | 0.84 | SIRT2 (0.36) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL12417528 | 0.84 | FOLH1 (0.33) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL13531987 | 0.83 | SIRT2 (0.41) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL277647 | 0.83 | SIRT2 (0.45) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL13339490 | 0.82 | SIRT2 (0.41) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL12417336 | 0.80 | HDAC4 (0.38) | SIRT2SIRT1HDAC4MEF2DEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | SIRT2 4150/4885SIRT1 3361/4885HDAC4 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.